Annexon: Accelerating Immunotherapy Platform with Multiple Milestones in 2026

Annexon is advancing its targeted immunotherapy platform for neuroinflammatory diseases with multiple registrational milestones in 2026. The company has filed a MAA for Tanruprubart, aiming to be the first fast-acting therapy for Guillain-Barré Syndrome. Vonaprument Phase 3 topline data for dry AMD with geographic atrophy is expected in H2 2026, and proof-of-concept data for ANX1502, an oral C1 inhibitor for autoimmune disease, is also expected in 2026. Annexon has a strong financial position, funding operations into late 2027.